147 related articles for article (PubMed ID: 29844203)
21. Morphologic heterogeneity of acute promyelocytic leukemia: therapy-related acute promyelocytic leukemia presenting with FAB-M2 morphology.
Sinha S; Aish L; Oo TH
Am J Hematol; 2006 Jun; 81(6):475-6. PubMed ID: 16680741
[No Abstract] [Full Text] [Related]
22. Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Liberante FG; Pouryahya T; McMullin MF; Zhang SD; Mills KI
Oncotarget; 2016 Feb; 7(6):6609-19. PubMed ID: 26735888
[TBL] [Abstract][Full Text] [Related]
23. Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia.
Scholl S; Lüftner J; Mügge LO; Schmidt V; Fricke HJ; Höffken K
Ann Hematol; 2007 Oct; 86(10):763-5. PubMed ID: 17639390
[No Abstract] [Full Text] [Related]
24. Spotlight on pembrolizumab in the treatment of advanced melanoma.
Rajakulendran T; Adam DN
Drug Des Devel Ther; 2015; 9():2883-6. PubMed ID: 26082618
[TBL] [Abstract][Full Text] [Related]
25. FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
Chuk MK; Chang JT; Theoret MR; Sampene E; He K; Weis SL; Helms WS; Jin R; Li H; Yu J; Zhao H; Zhao L; Paciga M; Schmiel D; Rawat R; Keegan P; Pazdur R
Clin Cancer Res; 2017 Oct; 23(19):5666-5670. PubMed ID: 28235882
[TBL] [Abstract][Full Text] [Related]
26. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab for patients with advanced melanoma.
Burki TK
Lancet Oncol; 2015 Jun; 16(6):e264. PubMed ID: 25921425
[No Abstract] [Full Text] [Related]
28. The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy.
Buckley SA; Othus M; Estey EH; Walter RB
Blood Cancer J; 2015 Jan; 5(1):e276. PubMed ID: 25635529
[No Abstract] [Full Text] [Related]
29. Faggot cells in an HIV-positive patient with inv(16)/therapy-related acute myeloid leukaemia.
Jerez A; del Mar Osma M; Amigo M; Ortuño FJ
Br J Haematol; 2010 Sep; 150(6):646. PubMed ID: 20666775
[No Abstract] [Full Text] [Related]
30. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
31. FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
Barone A; Hazarika M; Theoret MR; Mishra-Kalyani P; Chen H; He K; Sridhara R; Subramaniam S; Pfuma E; Wang Y; Li H; Zhao H; Zirkelbach JF; Keegan P; Pazdur R
Clin Cancer Res; 2017 Oct; 23(19):5661-5665. PubMed ID: 28179454
[TBL] [Abstract][Full Text] [Related]
32. High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML.
Tiacci E; Venanzi A; Ascani S; Marra A; Cardinali V; Martino G; Codoni V; Schiavoni G; Martelli MP; Falini B
N Engl J Med; 2018 Sep; 379(10):981-984. PubMed ID: 30184450
[No Abstract] [Full Text] [Related]
33. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Chan TS; Khong PL; Kwong YL
Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
[No Abstract] [Full Text] [Related]
35. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab for Recurrent Conjunctival Melanoma.
Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
[No Abstract] [Full Text] [Related]
37. A tale of two tumours and a plea for progress.
Fisher R; Cahalin P; Gore M; Larkin J
Lancet Oncol; 2012 Feb; 13(2):124-5. PubMed ID: 22300855
[No Abstract] [Full Text] [Related]
38. MK-3475 effective against melanoma.
Cancer Discov; 2014 Aug; 4(8):863-4. PubMed ID: 25092730
[No Abstract] [Full Text] [Related]
39. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.
Hulegårdh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf Å; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G; Stockelberg D; Lehmann S
Am J Hematol; 2015 Mar; 90(3):208-14. PubMed ID: 25421221
[TBL] [Abstract][Full Text] [Related]
40. Unusual hematologic malignancies. Case 2. Mediastinal germ cell tumor, malignant histiocytosis, and acute leukemia.
Vaishampayan U; Dan ME; Hussain M
J Clin Oncol; 2002 Sep; 20(17):3739-42. PubMed ID: 12202675
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
